Open-label Safety Study in Adults With ADHD

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3

Sunovion